• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Western Pac Surveill Response J . Replacement of SARS-CoV-2 strains with variants carrying N501Y and L452R mutations in Japan: an epidemiological s

tetano

Editor, Senior Moderator
Western Pac Surveill Response J


. 2022 Sep 16;13(3):1-10.
doi: 10.5365/wpsar.2022.13.3.943. eCollection 2022 Jul-Sep.
Replacement of SARS-CoV-2 strains with variants carrying N501Y and L452R mutations in Japan: an epidemiological surveillance assessment


Yusuke Kobayashi[SUP] 1 [/SUP], Takeshi Arashiro[SUP] 1 [/SUP], Miyako Otsuka[SUP] 1 [/SUP], Yuuki Tsuchihashi[SUP] 1 [/SUP], Takuri Takahashi[SUP] 1 [/SUP], Yuzo Arima[SUP] 1 [/SUP], Yura K Ko[SUP] 1 [/SUP], Kanako Otani[SUP] 1 [/SUP], Masato Yamauchi[SUP] 1 [/SUP], Taro Kamigaki[SUP] 1 [/SUP], Tomoko Morita-Ishihara[SUP] 2 [/SUP], Hiromizu Takahashi[SUP] 2 [/SUP], Sana Uchikoba[SUP] 2 [/SUP], Michitsugu Shimatani[SUP] 2 [/SUP], Nozomi Takeshita[SUP] 2 [/SUP], Motoi Suzuki[SUP] 1 [/SUP], Makoto Ohnishi[SUP] 3 [/SUP]



Affiliations

Abstract

Objective: Monitoring the prevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants is important due to concerns regarding infectivity, transmissibility, immune evasion and disease severity. We evaluated the temporal and regional replacement of previous SARS-CoV-2 variants by the emergent strains, Alpha and Delta.
Methods: We obtained the results of polymerase chain reaction screening tests for variants conducted in multiple commercial laboratories. Assuming that all previous strains would be replaced by one variant, the new variant detection rate was estimated by fitting a logistic growth model. We estimated the transmission advantage of each new variant over the pre-existing virus strains.
Results: The variant with the N501Y mutation was first identified in the Kinki region in early February 2021, and by early May, it had replaced more than 90% of the previous strains. The variant with the L452R mutation was first detected in the Kanto-Koshin region in mid-May, and by early August, it comprised more than 90% of the circulating strains. Compared with pre-existing strains, the variant with the N501Y mutation showed transmission advantages of 48.2% and 40.3% in the Kanto-Koshin and Kinki regions, respectively, while the variant with the L452R mutation showed transmission advantages of 60.1% and 71.9%, respectively.
Discussion: In Japan, Alpha and Delta variants displayed regional differences in the replacement timing and their relative transmission advantages. Our method is efficient in monitoring and estimating changes in the proportion of variant strains in a timely manner in each region.
 
Back
Top Bottom